Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 125,000 shares at $26.91 ($3.4M) on 2026-08-24, disclosed to the SEC on 2026-08-25.
Scheduled sale ($3.4M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NAMS | SELL | 2026-01-07 | $200K | — | Filing → |
| NAMS | SELL | 2025-08-25 | $3.7M | — | Filing → |
| NAMS | SELL | 2024-03-27 | $4.1M | — | Filing → |